MHRA Approves BetaGlue Therapeutics' YntraDose Clinical Trial for Unresectable Pancreatic Cancer
Key Insights
The UK's MHRA has approved BetaGlue Therapeutics (search)' clinical trial application for YntraDose (search), a novel radiotherapy device targeting unresectable locally advanced pancreatic ductal adenocarcinoma (search).
The early feasibility study will assess safety and performance of the innovative Yttrium-90 microsphere technology that delivers targeted radiation directly into tumor sites.
LA-PDAC (search) incidence has increased 1.0% annually since the late 1990s and is projected to become the second-leading cause of cancer-related mortality by 2030.
BetaGlue Therapeutics (search) announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved the clinical trial application for YntraDose (search) in unresectable locally advanced pancreatic ductal adenocarcinoma (search) (LA-PDAC (search)). The approval enables the clinical-stage oncology company to advance its innovative radiotherapy solution into human testing for one of the most challenging cancer types.
Novel Radiotherapy Technology Targets Aggressive Cancer
The approved clinical study represents an early feasibility investigation designed to assess safety and performance in patients with unresectable locally advanced pancreatic ductal adenocarcinoma (search). YntraDose (search) is a locoregional therapy intended for percutaneous radio-ablation of unresectable solid tumors, utilizing a novel approach that delivers targeted radiation doses through Yttrium-90 microspheres injected directly into the tumor site within a glue matrix that holds the Y-90 microspheres in place.
LA-PDAC (search) remains a significant health concern and represents a substantial unmet medical need in oncology. According to the company, the incidence of LA-PDAC has increased by 1.0% per year since the late 1990s, and the disease is projected to become the second-leading cause of cancer-related mortality by 2030.
Clinical Development Milestone
"The approval by the MHRA represents a fundamental milestone in the clinical development of YntraDose (search) and a meaningful step forward in our commitment to innovation in oncology," said Alexis Peyroles, CEO of BetaGlue Therapeutics (search). "This authorization enables us to initiate our first clinical study in the UK in Q1 2026, marking a critical step toward delivering a novel therapeutic option for patients with unresectable locally advanced pancreatic cancer (search), one of the most aggressive and deadly malignancies."
The CEO emphasized the collaborative effort behind this achievement, stating the company is "proud of the dedication shown by our team and Clinical Advisory Board and grateful for the collaborative engagement with regulatory authorities."
Platform Technology with Broader Applications
BetaGlue Therapeutics (search) is developing YntraDose (search) as a novel radiotherapy platform technology for the localized and targeted treatment of unresectable solid tumors. While currently being evaluated for LA-PDAC (search), the company indicates the technology has potential applications in other cancer indications beyond pancreatic cancer (search).
The planned Q1 2026 study initiation represents BetaGlue's first clinical investigation in the UK, marking a significant step in the company's clinical development program as it works to address the urgent need for effective treatments in this challenging patient population.